Investigators have discovered a new nanotechnological device for the treatment and prevention of neuropsychiatric and neurodegenerative diseases: lithium-loaded gold nanoparticles in the form of a nasal spray that delivers treatment directly to the brain.

The October issue of Psychiatric Times is now live! This month, we take closer look at the new INTEGRATE guidelines for the treatment of schizophrenia. Download the issue now and follow along as articles are shared throughout the month. https://t.co/5PIOWns0rN

🌟Our website has a brand new look! Check out the elevated design, easier navigation, and new Shorts feature—with quick, digestible insights for busy psychiatric clinicians. We are so proud to offer this digital experience as part of our 40th anniversary! https://t.co/IjFfHtkahi

The newly published International Guidelines for Algorithmic Treatment (INTEGRATE) represent an international effort to standardize schizophrenia care. How do they differ from typical practice? Learn more here: https://t.co/RrXB8M6uyG

A new study reveals the Reversal of Cognitive Decline program significantly reduces depression in patients with cognitive impairment, enhancing both mood and cognitive health.

Movement disorders are categorized into hyperkinetic and bradykinetic based on their clinical presentation, but distinct clinical entities often have features of both. 🧠 Check out our latest CME article to learn more:

Reproductive psychiatrist Sarah Oreck, MD, MS challenges the claims linking acetaminophen use in pregnancy to autism and ADHD.

Cognitive function is uniquely important in late-life depression, with at least 50% of patients experiencing decline.

🚨 BREAKING NEWS: The FDA has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau antibody in phase 2 development for the treatment of early #Alzheimer disease. Read more here:

Our October theme: Lifestyle Psychiatry. If you are interested in being featured in a future Special Report/print issue, submit to our content series! https://t.co/aydEf1ZKIH

The ongoing pivotal phase 3 clinical trial evaluating oral brexanolone (LPCN 1154) for the treatment of postpartum depression is on track, with one-third of planned participants randomly assigned. @LipocineInc

According to new phase 3 data, seltorexant showed comparable efficacy to quetiapine XR as an adjunctive treatment for major depressive disorder with insomnia symptoms. Andrew J. Cutler, MD, shares his thoughts on the latest data:

An ADHD diagnosis can be both challenging and clarifying. It can impact family dynamics, daily life, and long-term outcomes, from school performance to driving safety. Watch the expert-led conversation: https://t.co/0mXb5EFhm9

In this phase 2 MINDFuL trial, XPro demonstrated consistent positive trends across cognitive, neuropsychiatric, and biological endpoints in patients with early Alzheimer disease with inflammation, despite not meeting the trial's primary endpoint.

Polypharmacy and potentially inappropriate medication use is associated with adverse drug events, increased health care use, and greater health care costs. These risks are increased for adults 65 years and older. https://t.co/5qPXfcTnye

Hetlioz showed significant improvement in sleep latency in a phase 3 study for insomnia from @vandapharma, with effects persisting throughout the study duration.

New topline results for SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the endocannabinoid system that helps restore healthy brain functions. Read more here:

Apathy, defined as a quantitative reduction in goal-directed activity compared with a patient’s previous functioning, is highly prevalent and pervasive in patients with cognitive impairment.

Neuroplastic symptoms: real, physical symptoms (ie, not to be confused with malingering or factitious symptoms) caused by neuroplasticity in the brain rather than damage, disease, or dysfunction in the body. Learn more in our latest Special Report article: https://t.co/YLdvHKoQz9

The FDA has granted an expansion of the currently cleared treatment protocols for @BrainsWay deep transcranial magnetic stimulation to include accelerated protocol for patients with major depressive disorder and comorbid symptoms of anxiety.